X-linked inhibitor of apoptosis protein as a therapeutic target

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 11, 2007, Pages 1459-1471

  Dean, Emma J ^a,b   Ranson, Malcolm ^a   Blackhall, Fiona ^a   Dive, Caroline ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antisense; Apoptosis; Cancer; Inhibitor of apoptosis (IAP); Small molecule inhibitors; X linked inhibitor of apoptosis protein (XIAP)

Indexed keywords

AEG 35156; ANTISENSE OLIGONUCLEOTIDE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ARCHEXIN; BENZENESULFONAMIDE DERIVATIVE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CISPLATIN; CYTARABINE; DOCETAXEL; EMBELIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; INTERLEUKIN 2; LY 2181308; MESSENGER RNA; NUTILIN; PACLITAXEL; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; RX 0201; SMALL INTERFERING RNA; SURVIVIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DNA DAMAGE; DRUG MECHANISM; DRUG TARGETING; ESOPHAGUS CARCINOMA; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; MOLECULAR INTERACTION; NEUROPROTECTION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; RNA TRANSLATION; SIDE EFFECT; THROMBOCYTOPENIA; VIRAL GENE THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 36749062005     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.11.1459     Document Type: Review

References (104)

1. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
2. SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353:123-132.
3. SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an eastern cooperative oncology group (ECOG) trial - E4599. J. Clin. Oncol., 2005 ASCO Annual Meeting Proceedings (2005) 23(16S):4.
4. GIANTONIO BJ, CATALANO PJ, MEROPOL NJ: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the eastern cooperative oncology group (EGOC) study E3200. Program and Abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium. Hollywood, Florida, USA (27 - 29 January 2005):(Abstract 169a).
5. KERR JF, WYLLIE AH, CURRIE AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer (1972) 26:239-257.
6. RAFF M: Cell suicide for beginners. Nature (1998) 398(6707):119-122.
7. LEIST M, JAATTELA M: Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell Biol. (2001) 2(8):589-598.
8. KLUCK RM, BOSSEY-WETZEL E, GREEN DR, NEWMEYER DD: The release of cytochrome C from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science (1997) 275:1132-1136.
9. SALEH A, SRINIVASULA S, ACHARYA S, FISHEL R, ALNEMRI ES: Cytochrome C and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J. Mol. Chem. (1999) 274:17941-17945.
10. ZOU H, HENZEL WJ, LIU XLA, WANG X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome C-dependent activation of caspase-3. Cell (1997) 90:405-413.
11. ZOU H, LI Y, LIU X, WANG X: An APAF-1 cytochrome C mutimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. (1999) 274:11549-11556.
12. SHI Y: Mechanisms of caspase activation and activation and inhibition during apoptosis. Mol. Cell (2002) 9:459-470.
13. KISCHKEL FC, HELBARDT S, BEHRMANN I et al.: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signalling complex (DISC) with the receptor. EMBO J. (1995) 14(22):5579-5588.
14. KANG JJ, SCHABER MD, SRINIVASULA SM et al.: Cascades of mammalian caspase activation in the yeast Saccharomyces cervisiae. J. Biol. Chem. (1999) 274:3189-3198.
15. STENNICKE HR, JÜRGENSMEIER JM, SHIN HDQ et al.: Pro-caspase-3 is a major physiologic target of caspase-8. J. Biol. Chem. (1998) 273:27084-27090.
16. SALVESEN GS, DIXIT VM: Caspase activation: the induced-proximity model. Proc. Natl. Acad. Sci. USA (1999) 96:10964-10967.
17. COHEN GM: Caspases: the executioners of apoptosis. Biochem. J. (1997) 326(Part 1):1-16.
18. YIN XM: Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene (2006) 369:7-19.
19. CROOK NE, CLEM RJ, MILLER LK: An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. (1993) 67:2168-2174.
20. DEVERAUX QL, TAKAHASHI R, SALVESEN GS, REED JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature (1997) 388:300-304.
21. SUN C, CAL M, GUNASEKERA AH et al.: NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature (1999) 401:818-821.
22. ROTHE M, PAN MG, HENZEL WJ, AYRES TM, GODEDDEL DV: The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell (1995) 83:1243-1252.
23. UREN AG, COULSON EJ, VAUX DL: Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts. Trends Biochem. Sci. (1998) 23:159-162.
24. SALVESEN GS, DUCKETT CS: IAP proteins: blocking the road to deaths door. Nat. Rev. Mol. Cell Biol. (2002) 3:401-410.
25. VERHAGEN AM, COULSON EJ, VAUX DL: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. (2001) 2:3001-3010.
26. LI F, AMBROSINI G, CHU EY et al.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 396:580-584.
27. DEVERAUX QL, ROY N, STENNICKE HR et al.: IAPs block apoptotic events induced by caspase-8 and cytochrome C by direct inhibition of distinct caspases. EMBO J. (1998) 17:2215-2223.
28. TAKAHASHI R, DEVERAUX Q, TAMM I et al.: A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. (1998) 273:7787-7790.
29. SRINIVASULA SM, HEGDE R, SALEH A et al.: A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature (2001) 410:112-116 [Erratum in Nature (2001) 2411(6841):10811.
30. DAN H, SUN M, KANEKO S et al.: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. (2004) 279(7):5405-5412.
31. SUZUKI Y, NAKABAYASHI Y, TAKAHASHI R: Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl. Acad. Sci. USA (2001) 98:8662-8667.
32. YANG Y, FANG S, JENSEN JP, WEISSMAN AM, ASHWELL JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 288:874-877.
33. DUCKETT CS, NAVA VE, GEDRICH RW et al.: A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors. EMBO J (1996) 15:2685-2689.
34. DEVERAUX QL, LEO E, STENNICKE HR et al.: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. (1999) 18:5242-5251.
35. CHEN Z, NAITO M, HORI S et al.: A human IAP-famfly gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun. (1999) 264:847-854.
36. VUCIC D, STENNICKE HF, PISABARRO MT, SALVESEN GS, DIXIT VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. (2000) 10:1359-1366.
37. KASOF GM, GOMES BC: Livin, a novel inhibitor of apoptosis protein family member. J. Biol. Chem. (2001) 276:3238-3246.
38. RICHTER BWM, MIR SS, EIBEN LJ et al.: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol. Cell Biol. (2001) 21:4292-4301.
39. LISTON P, FONG WG, KORNELUK RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene (2003) 22:8568-8580.
40. MAIER JK, LAHOUA Z, GENDRON NH et al.: The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J. Neurosci. (2002) 15:2035-2043.
41. AMBROSINI G, ADIDA C, ALTIERI DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. (1997) 3:917-921.
42. HAUSER HP, BARDROFF M, PYROWOLAKIS G, JENTSCH S: A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J. Cell Biol. (1998) 141:1415-1422.
43. HAO Y, SEKINE K, KAWABATA A et al.: Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat. Cell Biol. (2004) 6:849-860.
44. GIANANI R, JARBOE E, ORLICKY D et al.: Expression of survivin in normal, hyperplastic and neoplastic colonic mucosa. Hum. Pathol. (2001) 32:119-125.
45. TANAKA K, IWAMOTO S, GON G et al.: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. (2000) 6: 127-134.
46. TAMM I, WANG Y, SAUSVILLE E et al.: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. (1998) 58:5315-5320.
47. CONWAY EM, POLLEFEYT S, CORNELISSEN J et al.: Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood (2000) 95:1435-1442.
48. LEWIS J, BURSTEIN E, REFFEY SB et al.: Uncoupling of the signaling and caspase-inhibitory properties of X-linked inh,ibitor of apoptosis. J. Biol. Chem. (2004) 279:9023-9029.
49. KARIN M, LIN A. NF-κB at the crossroads of life and death. Nat. Immunol. (2002) 3:221-227.
50. CLAVERIA C, CAMINERO E, MARTINEZ AC, CAMPUZANO S, TORRES M: GH3, a novel proapoptonic domain in Drosophila Grim, promotes a mitochodrial deeath pathway. EMBO J. (2002) 21:3327-3336.
51. DU C, FANG M, LI Y, LI L, WANG X: Smac, a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 102:33-42.
52. VERHAGEN AM, SILKE J, EKERT PG et al.: HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J. Biol. Chem. (2002) 277:445-454.
53. VERHAGEN AM, EKERT PG, PAKUSCH M et al.: Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 102:43-53.
54. HEGDE R, SRINIVASULA SM, ZHANG Z et al.: Identification of Omi/ HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem. (2002) 277:432-438.
55. SUZUKI Y, IMAI Y, NAKAYAMA HTK, TAKIO K, TAKAHASHI R: A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell (2001) 8:613-621.
56. TAMM I, KORNBLAU SM, SEGALL H et al.: Expression and prognostic significance of IAP-family genes in human cancer and myeloid leukemias. Clin. Cancer Res. (2000) 6:1796-1803.
57. TAMM I, RICHTER S, OLTERSDORF D et al.: High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin. Cancer Res. (2004) 10:3737-3744.
58. RAMP U, KRIEG T, CALISKAN E et al.: XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum. Pathol. (2004) 35(8):1022-1028.
59. MIZUTANI Y, NAKANISHI H, LI YN et al.: Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int. J. Oncol. (2007) 30(4):919-925.
60. NAKAGAWA Y, ABE S, KURATA M et al.: IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am. J. Hematol. (2006) 81(11):824-831.
61. LI M, SONG T, YIN ZF, NA Y: XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Clin. Med. J. (Engl.) (2007) 120(6):469-473.
62. FERREIRA CG, VAN DER VALK P, SPAN SW et al.: Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in tactically resected non-small cell lung cancer patients. Clin. Cancer Res. (2001) 7:2468-2474.
63. FERREIRA CG, VAN DER VALK P, SPAN SW et al.: Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann. Oncol. (2001) 12:799-805.
64. ESPINOSA M, CANTU D, HERRERA N et al.: Inhibitors of apoptosis proteins in human cervical cancer. BMC Cancer (2006) 27(6):45.
65. WILKINSON JC, CEPERO E, BOISE LH, DUCKETT CS: Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol. Cell Biol. (2004) 24:7003-7014.
66. BEREZOVSKAYA O, SCHIMMER AD, GLINSKII AB et al.: Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. (2005) 65:2378-2386.
67. HOLCIK M, YEH C, KORNELUK RG, CHOW T: Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increase resistance to radiation induced cell death. Oncogene (2000) 19:4174-4177.
68. LACASSE EC, BAIRD S, KORNELUK RG, MACKENZIE AE: The inhibitors of apoptosis IAPs and their emerging role in cancer. Oncogene (1998) 17:3247-3259.
69. SASAKI H, SHENG Y, KOTSUJI F, TSANG BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemresistant human ovarian cancer cells. Cancer Res. (2000) 60:5659-5666.
70. CHAWLA-SARKAR M, BAE SI, REU FJ et al.: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell(2004) 11:915-923.
71. MCMANUS DC, LEFEBVRE CA, CHERTON-HORVAT G et al.: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeurics. Oncogene (2004) 23:8105-8117.
72. TONG QS, ZHENG LD, WANG L et al.: Downregulation of XIAP expression induces apoptosis and enhances chenotherapeuric sensitivity in human gastric cancer cells. Cancer Gene Ther. (2005) 12:509-514.
73. LI F, ACKERMANN EJ, BENNETT CF et al.: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. (1999) 1:461-466.
74. HARLIN H, BIRKEY REFFEY S, DUCKETT CS, LINDSTEN T, THOMPSON CB: Characterization of XIAP-deficient mice. Mol. Cell Biol. (2001) 21:3604-3608.
75. CROOKE ST: Molecular mechanisms of antisense drugs: RNAaseH. Antisense Nucleic Acid Drug Dev. (1998) 8:133-134.
76. BILIM V, KASAHARA T, HARA N, TAKAHASHI K, TOMITA Y: Role of XIAP in the malignant phenotype of translational cell cancer (TCC) and therapeutic activity in XIAP antisense oligonucleotides against multidnig-resistance TCC in vitro. Int. J. Cancer (2003) 103:29-37.
77. CAO C, MU Y, HALLAHAN DE, LU B: XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene (2004) 23:7047-7052.
78. RANSON M, DIVE C, WARD T et al.: A Phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors. J. Clin. Oncol., ASCO Annual Meeting Proceedings Part I (2006) 24(18S):3059.
79. CHEN J, XIAO XQ, DENG CM, SU XS, LI GY: Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2. J. Chemother. (2006) 18(5):525-531.
80. ZHANG S, DING F, LUO A et al.: XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol. Ther. (2007) 6(6):[Epub ahead of print].
81. GIAGKOUSIKLIDIS S, VELLANKI SH, DEBATIN KM, FULDA S: Sensitization of pancreatic carcinoma cells for γ-irradiation-induced apoptosis by XIAP initibition. Oncogene (2007):[Epub ahead of print].
82. MCMANUS DC, LEFEBVRE CA, CHERTON-HORVAT G et al.: Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene (2004) 23(49):8105-8117.
83. SHIOZAKI EN, CHAI J, RIGOTTI DJ et al.: Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell (2003) 11:519-527.
84. OOST TK, SUN C, ARMSTRONG RC et al.: Discovery of potent antagonsits of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. (2004) 47:4417-4426.
85. ARNT CR, CHIOREAN MV, HELDEBRANT MP, GORES GJ, KAUFMANN SH: Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. (2002) 277:44236-44243.
86. YANG L, MASHIMA T, SATO S et al.: Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. (2003) 63:831-837.
87. FULDA S, WICK W, WELLER M, DEBATIM KM: Smac agonists sensitize for TRAIL/ Apo2L- or anticancer drug-induced apoptosis and induce regression of human glioma xenografts. Nat. Med. (2002) 8:808-815.
88. LI L, THOMAS RM, SUZUKI H et al.: A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death. Science (2004) 305:1471-1474.
89. SUN H, NIKOLOVSKA-COLESKA Z, LU J et al.: Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J. Med. Chem. (2006) 49(26):7916-7920.
90. NIKOLOVSKA-COLESKA Z, XU L, HU Z et al.: Discovery of embelin as a cell-permeable, small-molecule weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicin three-dimensional structure database. J. Med. Chem. (2004) 47:2430-2440.
91. SCHIMMER AD, WEILSH K, PINILLA C et al.: Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumour activity. Cancer Cell (2004) 5:25-35.
92. WANG Z, CUDDY M, SAMUEL T et al.: Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J. Biol. Chem. (2004) 279:48168-48176.
93. KARIKARI CA, ROY I, TRYGGESTAD E et al.: Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol. Cancer Ther. (2007) 6:957-966.
94. WU TY, WAGNER KW, BURSULAYA B, SCHULTZ PG, DEVERAUX QL: Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/ caspase-3 interaction. Chem. Biol. (2003) 10:759-767.
95. YAGIHASHI A, ASANUMA K, NAKAMURA M et al.: Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin. Chem. (2001) 47(9):1729-1731.
96. YAGIHASHI A, OHMURA T, ASANUMA K et al.: Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin. Chim. Acta (2005) 362(1-2).
97. ROHAYEM J, DIESTELKOETTER P, WEIGLE B et al.: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. (2000) 60(7):1815-1817.
98. RAMI A, AGARWAL R, SPAHN A: Synergetic effects of caspase 3 and μ-calpain in XIAP-breakdown upon focal cerebral ischemia. Neurochem. Res. (2007).
99. KEANE RW, KRAYDIEH S, LOTOCKI G et al.: Apoptotic and anti-apoptotic mechanisms following spinal cord injury. J. Neuropathol. Exp. Neurol. (2001) 60(5):422-429.
100. EBERHARDT O, COELLN R, KUGLER S et al.: Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetathydropyridine model of Parkinson's disease. J. Neurosci. (2000) 20:9126-9134.
101. WAGENKNECHT B, HERMISSON M, GROSCURTH P et al.: Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome C release. J. Neurochem. (2000) 75:2288-2297.
102. LEONARD K, PETRIN D, COUPLAND S et al.: XIAP protection of photoreceptors in animal models of retinitis pigmentosa. PLoS One (2007) 2:E314.
103. COOPER L, CHAN D, ROEDIGER F et al.: AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otol. Neurotol. (2006) 27(4):484-490.
104. CUMMINGS J, WARD TH, LA CASSE E et al.: Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer (2005) 92:532-538.